Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
June 1, 2020
Date of Patent:
January 25, 2022
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: The present invention provides a stable, non-aqueous, ready-to-use parenteral composition comprising: carfilzomib or pharmaceutically acceptable salt thereof, acidifying agent, optionally a surfactant, one or more solvents or co-solvents.
Type:
Grant
Filed:
April 25, 2017
Date of Patent:
January 18, 2022
Inventors:
Mailatur Sivaraman Mohan, Hiren Patel, Bhaveshkumar Vallabhbhai Patel, Raghu Kannekanti, Mohammad Raheesh
Abstract: The present invention relates to antimicrobial polymyxin derivative compounds and their uses, and in particular to peptide polymyxin antibiotics which may be used in the treatment of bacterial infections such as Gram negative bacterial infections, particularly those caused by multidrug-resistant (MDR) Gram negative bacterial infections.
Type:
Grant
Filed:
September 29, 2016
Date of Patent:
January 18, 2022
Assignee:
Monash University
Inventors:
Kade D. Roberts, Jian Li, Tony Velkov, Roger L. Nation, Philip E. Thompson
Abstract: The invention provides structurally-constrained peptides by hydrocarbon stapling of a BCL9 HD2 helix for use as a therapeutic agent. The invention further provides methods and kits for use of the structurally-constrained peptide of the instant invention. The invention is based, at least in part, on the results provided herein demonstrating that hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, possess superior pharmacokinetic properties compared to the corresponding unmodified peptides, and are highly effective in binding to ?-catenin in vitro, in cellulo, and in vivo, disrupting the BCL9/?-catenin interaction, and thereby interfering with deregulated Wnt/?-catenin signaling for therapeutic benefit in a variety of human diseases including human cancer.
Type:
Grant
Filed:
May 18, 2020
Date of Patent:
January 11, 2022
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
Loren D. Walensky, Ruben Carrasco, Gregory H. Bird
Abstract: In certain aspects, disclosed herein are novel compositions and methods related to either the enhancement or inhibition of erythropoiesis that are useful, for example, in the treatment of anemia or erythrocytosis.
Type:
Grant
Filed:
September 14, 2017
Date of Patent:
December 21, 2021
Assignees:
President and Fellows of Harvard College, University of Massachusetts
Inventors:
Merav Socolovsky, Allon M. Klein, Samuel Wolock, Betsabeh K. Tusi, Yung Hwang, Caleb Weinreb
Abstract: The present invention relates to a protective solution for preventing or reducing reperfusion injury of the brain which contains magnesium ions and which has an osmolality of 350 to 600 mOsm/L, a pH value of 6.8 to 7.8 and albumin in an amount of 1 to 20% by weight.
Type:
Grant
Filed:
May 19, 2020
Date of Patent:
November 30, 2021
Assignee:
ResuSciTec GmbH
Inventors:
Christoph Benk, Friedhelm Beyersdorf, Georg Trummer
Abstract: The present invention relates to a stabilized external preparation comprising thymosin beta 4 (T?4) as an active ingredient. More specifically, the present invention relates to a therapeutically effective external preparation with improved stability and biological activity of T?4. The preparation according to the present invention provides T?4 in a stable state by maintaining the biological activity of T?4 and minimizing the generation of T?4 sulfoxide through oxidization reactions and multimers through aggregation.
Type:
Grant
Filed:
August 4, 2017
Date of Patent:
November 23, 2021
Assignee:
G-TREEBNT CO., LTD.
Inventors:
Jun Won Choi, Kyoungsun Kim, Si Young Lee, Tae Heum Um
Abstract: The subject matter of this invention is directed towards chemically and thermodynamically stable glucagon analogs that are resistant to deamidation and fibrillation. The invention further discloses improved methods for the recombinant expression and purification of glucagon analogs.
Type:
Grant
Filed:
June 9, 2017
Date of Patent:
November 23, 2021
Assignee:
AmideBio, LLC
Inventors:
Michael H. B. Stowell, Mikhail Plam, Yanyu Peng
Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.
Type:
Grant
Filed:
December 19, 2016
Date of Patent:
November 9, 2021
Assignee:
FRESENIUS KABI IPSUM S.R.L
Inventors:
Antonio Ricci, Jacopo Zanon, Walter Cabri, Ivan Guryanov, Andrea Orlandin, Barbara Biondi, Fernando Formaggio, Dario Visentini
Abstract: Described is a composition comprising a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2, and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.
Type:
Grant
Filed:
June 4, 2020
Date of Patent:
November 2, 2021
Assignee:
Apeptico Forschung UND Entwicklung GMBH
Inventors:
Bernhard Fischer, Rudolf Lucas, Hendrik Fischer
Abstract: The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.
Abstract: Disclosed herein is a synthetic polypeptide with “n” number of repeats of a sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. The synthetic polypeptide as disclosed herein is represented by an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5. The synthetic polypeptide of the present disclosure is used to prepare synthetic elastomeric hydrogel. Also, disclosed are the methods of preparing the synthetic polypeptide and the elastomeric hydrogel along with their uses.
Abstract: The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.
Type:
Grant
Filed:
October 6, 2017
Date of Patent:
October 19, 2021
Assignees:
Clemson University Research Foundation, MUSC Foundation for Research Development
Inventors:
Ying Mei, Jia Jia, Chung-Jen James Chou
Abstract: The application concerns tissue inhibitor of metalloproteinase 3 (TIMP-3) muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them; in particular, muteins of TIMP-3 with specific amino acid substitutions in order to introduce N-linked glycosylation sites.
Type:
Grant
Filed:
August 26, 2015
Date of Patent:
October 19, 2021
Assignee:
Amgen Inc.
Inventors:
Jason C. O'Neill, Randal R. Ketchem, Taeweon Lee, Vishnu Chintalgattu, Jennitte Leann Stevens
Abstract: Modulators of melanocortin receptors (MCR) are provided herein. An MC5R peptide ligand is represented by to Formula 1: R1-Nle4-c[Xaa5-Yaa6-(NMe)D-Nal(2?)7-Arg8-Trp9-(NMe)Zaa10]-R2. R1 can be an acetyl, a glycosylated amino acid, —CO—(CH2)nCH3, or —CO—(CH2)nCF3 with n ranging from 1 to 6. R2 can be an —CONH2, —COOH, or —CH2OH. Xaa, Yaa, and Zaa can each be a natural amino acid or an unnatural amino acid.
Type:
Grant
Filed:
June 4, 2019
Date of Patent:
September 21, 2021
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.
Type:
Grant
Filed:
January 29, 2019
Date of Patent:
September 14, 2021
Assignee:
Extend Biosciences, Inc.
Inventors:
Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
Abstract: The present invention refers to a composition, comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand, and at least one further ingredient, a method for preparing said composition and the use of hemoglobin or myoglobin charged with a non-oxygen ligand for external treatment of wounds.
Abstract: Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).
Type:
Grant
Filed:
April 11, 2017
Date of Patent:
September 7, 2021
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.
Type:
Grant
Filed:
August 8, 2013
Date of Patent:
August 31, 2021
Assignee:
Hamlet Pharma AB
Inventors:
Catharina Svanborg, Manoj Puthia, Chin Shing Ho
Abstract: Disclosed are recombinant polypeptides that include (a) a filaggrin amino acid sequence and (b) a cell importation signal sequence that includes a motif of two to fifteen amino acids, wherein the motif includes at least one arginine residue and at least one methionine residue. Also disclosed are nucleic acids encoding the recombinant polypeptides of the present invention, and compositions that include the recombinant polypeptides and nucleic acids of the present invention. Methods of treating or preventing a skin disease or skin disorder using the compositions of the present invention are also included, as well as kits that include a sealed containing that includes a recombinant polypeptide of the present invention.
Type:
Grant
Filed:
January 8, 2019
Date of Patent:
August 24, 2021
Assignee:
Research Development Foundation
Inventors:
J. Timothy Stout, Binoy Appukuttan, Trevor McFarland